

Bevacizumab NO16966

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

PFS



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Bevacizumab NO16966

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival


1



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with metastatic carcinoma of the colon or rectum

Experimental Arm: Bevacizumab + FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) or CAPOX (Capecitabine)

Control Arm: Placebo for Bevacizumab



